Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8773035 | 0.79 | ALDH1A1 (0.48) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL8908162 | 0.77 | CHRNB2 (0.58) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL17139823 | 0.76 | ALDH1A1 (0.43) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL996345 | 0.76 | ALDH1A1 (0.54) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL8909377 | 0.76 | ALDH1A1 (0.54) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL7772397 | 0.76 | ALDH1A1 (0.54) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL8773025 | 0.75 | ALDH1A1 (0.48) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL11686451 | 0.75 | ALDH1A1 (0.48) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL15303488 | 0.74 | ALDH1A1 (0.52) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL10647273 | 0.74 | ALDH1A1 (0.52) | ALDH1A1ATMTSHRHPGDHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2058300-B1 | SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION | DAINIPPON SUMITOMO PHARMA CO (JP) | 2013-01-09 | — | — | EP | claimed |
| EP-1809288-B1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INST NAT SANTE RECH MED (FR) | 2011-09-14 | — | — | EP | claimed |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) | 2009-06-11 | — | — | US | claimed |
| EP-1946747-A1 | Pharmaceutical composition of improved stability containing taxane derivatives | Sandoz AG (CH) | 2008-07-23 | — | — | EP | claimed |
| EP-1809288-A1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2007-07-25 | — | — | EP | claimed |
| WO-2006051489-A1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-05-18 | — | — | WO | claimed |
| US-5438072-A | Taxane derivatives in a surface active agent; antitumor and anticarcinogenic agents | RHONE-POULENC RORER S.A. (FR) | 1995-08-01 | — | — | US | claimed |
| US-9044478-B2 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2015-06-02 | — | — | US | disclosed |
| CN-101511819-B | Derivatives of N- (amino-heteroaryl) -1H-indole-2-amides, preparation thereof and use thereof in therapy | SANOFI AVENTIS | 2014-04-23 | — | — | CN | disclosed |
| EP-1809288-B1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INST NAT SANTE RECH MED (FR) | 2011-09-14 | — | — | EP | disclosed |
| CN-101511819-A | Derivatives of N- (amino-heteroaryl) -1H-indole-2-amides, preparation thereof and use thereof in therapy | SANOFI AVENTIS (FR) | 2009-08-19 | — | — | CN | disclosed |
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | UNIVERSITE DU DROIT ET DE LA SANTE- LILLE II (FR) | 2009-06-11 | — | — | US | disclosed |
| EP-1946747-A1 | Pharmaceutical composition of improved stability containing taxane derivatives | Sandoz AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2006051489-A1 | USE OF 1,4-BIS (3-AMINOALKYL) PIPERAZINE DERIVATIVES IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-05-18 | — | — | WO | disclosed |
| CN-1154653-C | Peptides and methods of making the same | ��ķ����ŵ | 2004-06-23 | — | — | CN | disclosed |
| EP-0832900-B1 | PEPTIDE AND METHOD OF OBTAINING IT | IMMUNOTECH DEV INC (CA) | 2004-03-03 | — | — | EP | disclosed |
| EP-0832900-A4 | PEPTIDE AND METHOD OF OBTAINING IT | IMMUNOTECH DEV INC (RU) | 1999-10-06 | — | — | EP | disclosed |
| CN-1189837-A | Peptides and methods of making the same | DEIGIN VLADISLAV ISAKOVICH (RU) | 1998-08-05 | — | — | CN | disclosed |
| WO-1996040740-A1 | PEPTIDE AND METHOD OF OBTAINING IT | DEIGIN VLADISLAV ISAKOVICH (RU) | 1996-12-19 | — | — | WO | disclosed |
| EP-0049658-A1 | Substituted imino diacids, their preparation and pharmaceutical preparations containing them | ADIR (FR) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149464-A1 | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases | PSEN1, PSEN2, SNCA | ALDH1A1 129/4885ATM 3696/4885TSHR 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.